M200 (Volociximab) + Liposomal Doxorubicin + M200 (Volociximab) + M200 (Volociximab)
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer, Primary Peritoneal Cancer
Conditions
Ovarian Cancer, Primary Peritoneal Cancer
Trial Timeline
Jul 1, 2007 → Oct 1, 2009
NCT ID
NCT00635193About M200 (Volociximab) + Liposomal Doxorubicin + M200 (Volociximab) + M200 (Volociximab)
M200 (Volociximab) + Liposomal Doxorubicin + M200 (Volociximab) + M200 (Volociximab) is a phase 1/2 stage product being developed by AbbVie for Ovarian Cancer, Primary Peritoneal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00635193. Target conditions include Ovarian Cancer, Primary Peritoneal Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00635193 | Phase 1/2 | Completed |
Competing Products
20 competing products in Ovarian Cancer, Primary Peritoneal Cancer